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Abstract
Background: Parathyroid carcinoma is a rare malignancy, with an incidence of 0.5 to 4% of all
cases of primary hyperparathyroidism. Surgery is the only curative treatment.
Case presentation: We report the case of a 66-year-old man referred for a large suspicious
substernal goitre associated with severe hypercalcemia due to hyperparathyroidism. After
normalization of serum calcium levels, patient underwent surgery. The voluminous
cervicomediastinal firm mass could not be removed through the cervical incision; therefore a
cervicothoracic approach was employed. Histopathology revealed a giant parathyroid cancer of 450
grams. A review of the literature was also undertaken to summarize the current treatment
approaches for this rare malignancy.
Conclusion:  Parathyroid cancer is usually not recognized either preoperatively or intra-
operatively. En bloc resection of the tumour with the adjacent tissue is the treatment of choice and
it is very important to avoid the rupture of the capsule during operation. Neither tumour size, nor
the lymph node status appears to play a role in prognosis. The management of parathyroid
carcinoma is a challenge even for experienced surgeons.
Background
Parathyroid Carcinoma (PC) is a rare malignancy with an
incidence of 0.5 to 4% in all patients surgically treated for
primary hyperparathyroidism [1,2]. Generally the tumour
is solitary, although recently a double parathyroid carci-
noma has been reported [3]. This tumour has a high prob-
ability to recur locally and to spread to regional nodes and
distant sites. It is difficult to diagnose parathyroid cancer
preoperatively. Often local invasion at operation and sub-
sequent histological examination reveal malignancy and
differentiation from a benign parathyroid adenoma can
be difficult even after histological examination. However,
the presence of some signs such as profound hypercal-
cemia, markedly elevated levels of parathormone and a
clinically palpable cervical mass can raise suspicion pre-
operatively of a malignant lesion [1,2,4,5].
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We report the case of a patient admitted to our depart-
ment for a large substernal goitre suspected to be a thyroid
cancer, associated with severe hyperparathyroidism.
Case presentation
A 66-year-old man was referred with a diagnosis of hyper-
parathyroidism, mild renal failure, peptic ulcer and large
suspicious cervico-mediastinal goitre. The patient had
fatigue, anaemia, anorexia and bone pain for several
months. The fine needle aspiration of the neck mass, per-
formed before the admission showed the presence of
malignant cells. Preoperative laboratory findings are
reported in table 1.
Ultrasonography of the neck showed an enlarged thyroid
gland with substernal extension; many solid nodules and
some calcifications were present. The computerised tom-
ographic (CT) scan showed a large solid mass in left neck,
with extension to the mediastinum, and displacement of
the trachea, oesophagus and great vessels (Figure 1). Tra-
cheobronchoscopy demonstrated substenosis of the prox-
imal trachea due to extrinsic compression.
Tc-99m sestamibi scintigraphy demonstrated diffuse radi-
opharmaceutical uptake within the thyroid region and the
lower portion of the neck. This tracer accumulation corre-
sponded to the mass and it was persistent during the dif-
ferent phases of the scintigraphy without significant
changes (Figure 2). The lack of a spot area of increased
MIBI uptake ruled out the diagnosis of adenoma. The
scintigraphic pattern was classified as due to a multinod-
ular goitre.
The patient was vigorously hydrated and bisphospho-
nates were given preoperatively to control hypercalcemia.
Eight days later the serum calcium level decreased to 10.4
mg/dl. With the above clinical findings, the patient under-
went surgical neck exploration.
At surgery a voluminous cervicomediastinal firm mass
was found that could not be removed via the superior tho-
racic strait; therefore a complete sternotomy was per-
formed. The surgical findings revealed an ovoid, grayish-
yellow, hard mass, measuring 12 × 9 × 8 cm, adherent to
the base of the left lobe of the thyroid, extending to the
anterior upper mediastinum; the recurrent laryngeal nerve
was laterally displaced but not invaded. Therefore en bloc
resection of the mass along with the total thyroid gland
and the connective tissue apparently involved in the
tumour was performed. All the lymphoid tissue from the
ipsilateral tracheoesophageal groove to the upper medi-
astinum was removed
The histological report described a parenchymatous thy-
roid gland, with a subcapsular gelatinous nodule (1 cm
diameter). The voluminous tumour adherent to the base
of left lobe was multinodular, greyish-yellow. Histologi-
cally many fibrous bands of acellular collagenous tissue
extending from the thickened capsule, subdivided the
neoplasm into irregular compartments. The tumour cells,
arranged in trabecular and solid sheets, were homogene-
ous; they showed round – ovoid nuclei, with evident
nucleoli, and clear cytoplasm; occasionally cytoplasm was
abundant, eosinophilic and granular; nuclei were pleo-
morphic; mitoses were present (3 per 10 HPF). Rare
multinucleated osteoclastic-like giant cells were found
around foci of haemorrhage; necrosis and coarse calcifica-
tions were observed. Both capsular and vascular invasion
were present at the periphery of neoplasm. In the infil-
trated adjacent adipose tissue, well-circumscribed, encap-
sulated nodules of tumour, with a peripheral rim of
lymphoid tissue were found; they were considered to be
metastatic lymph nodes. Final diagnosis was a parathy-
roid carcinoma (Figure 3a, 3b, 3c, 3d). The postoperative
course was complicated by transient oligouria, with wors-
ening the chronic renal failure.
The patient also had severe postoperative hypocalcaemia,
necessitating calcium and vitamin D therapy. The postop-
erative laboratory values at hospital discharge are shown
in table 1. Figure 4 shows the change of serum Calcium
and PTH levels during patient's hospitalization
Table 1: Laboratory values
Preoperative laboratory values Postoperative laboratory values
Creatinine 2.30 mg/dl (0.60 – 1.30) 4.00 mg/dl (0.60 – 1.30)
ALP 825 U/L (50 – 140) 500 U/L (50 – 140)
Calcemia 14.2 mg/dl (8.4 – 10.5) 6.3 mg/dl (8.4 – 10.5)
Phosphorous 3.1 mg/dl (2.5 – 5.0) 2.4 mg/dl (2.5 – 5.0)
PTH 1828 pg/ml (10.0 – 65.0) 20.9 pg/ml (10.0 – 65.0)
ALP alcaline phosphatase PTH parathyroid hormoneWorld Journal of Surgical Oncology 2005, 3:39 http://www.wjso.com/content/3/1/39
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At follow-up, three, six, nine and 12 months after surgery,
the patient was disease-free with normal levels of PTH and
calcaemia and improvement of the bone disease symp-
toms. Whole body positron emission tomography (PET)
performed one year after surgery was negative.
Discussion
Parathyroid carcinoma is a rare disease and the preopera-
tive diagnosis is often difficult because clinical manifesta-
tions are similar, although more often severe than in
patients with parathyroid adenomas. Parathyroid carcino-
mas are generally larger and firmer than parathyroid ade-
nomas. The clinical manifestations of
hyperparathyroidism are usually more severe, and serum
levels of calcium, PTH and alkaline phosphatase are sig-
nificantly higher than in patients with adenoma. Patients
with parathyroid carcinoma have a high incidence of
renal dysfunction, osteoporosis and gastrointestinal
symptoms [1,2,4].
Preoperative and intraoperative suspicion is important in
planning the effective surgical treatment: the complete
resection of the tumour at the first neck exploration is
reported to provide the best chance of cure. The optimal
surgical treatment is en bloc resection with ipsilateral thy-
roid lobectomy and removal of any enlarged or abnormal
lymph nodes. Most of the authors emphasize the
importance of an aggressive initial approach in reducing
local and distant recurrences [4,6-12]. Particular attention
must be given to avoid rupture of the tumour during sur-
CT Scan showing a large solid left neck mass, with extension to the mediastinum and displacement of the trachea, oesophagus  and great vessels Figure 1
CT Scan showing a large solid left neck mass, with extension to the mediastinum and displacement of the trachea, oesophagus 
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gery, because of the very high risk of local seeding and per-
sistent or recurrent disease [4,13]; in these cases, local
surgical excision is useful for palliation but is rarely cura-
tive [14,15].
The management of the recurrent laryngeal nerve is more
controversial but it should be resected only when it is not
functioning preoperatively or is invaded by tumour
[1,4,15,16]. The clinical behaviour of parathyroid carci-
noma is variable, some patients are cured, others have an
indolent course; recurrent or persistent disease occurs in
about 50% of cases; usually the tumour recurs within 3
years after initial operation, although much longer inter-
vals have been described [4,6,17,18]. Surgery is the treat-
ment of choice even for recurrent and persistent disease
when the site of tumour can be localized: lung metastases
are the most frequent type of recurrences after local recur-
rences; Hundley et al, have recently reported a case of
resection of multiple PC lung metastases 20 years after the
initial neck surgery, with a significant improvement of
clinical and metabolic complications after removal of
metastatic parathyroid cancer from both lungs [19].
Surgery is also important to palliate hypercalcemia-associ-
ated metabolic complications and symptoms and to pro-
long survival [4,6,7,10,15,20,21].
Recently some authors have reported a role for adjuvant
radiation therapy. Neck and mediastinum adjuvant
irradiation has been reported to be useful in reducing the
risk of loco-regional disease progression and in improving
Sestamibi scintigraphy: diffuse enlargement of the thyroid gland associated with irregular uptake of the radionuclide Figure 2
Sestamibi scintigraphy: diffuse enlargement of the thyroid gland associated with irregular uptake of the radionuclide.World Journal of Surgical Oncology 2005, 3:39 http://www.wjso.com/content/3/1/39
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survival [16,22-24]. Other reports suggest a positive effect
of radiotherapy for palliating symptoms of hypercalcae-
mia in inoperable patients [23-25].
In our case, although the laboratory data revealed marked
hyperparathyroidism and the patient had all the signs and
symptoms of severe hyperparathyroidism, none of the
preoperative localizing studies raised suspicion of the
presence of a parathyroid carcinoma. The slow growth of
the mass and the preoperative FNAB suggested a large sub-
sternal goitre with malignant transformation; only the
postoperative histological exam revealed a diagnosis of
parathyroid cancer.
This is an interesting case because of the large size of the
parathyroid cancer with regional nodal metastases with-
out any evidence of distant metastases or local recurrence
one year after initial surgery. In the literature parathyroid
cancers ranges from 1.5 to 6 cm in diameter and from 1.5
to 27 grams in weight [18,26]. A case of giant paratyroid
carcinoma of 1200 grams with nodal involvement, pre-
senting as a substernal goitre has been reported; it was "en
bloc" resected and the patient was alive and disease free
after 4 years [27]. The tumour size does not appear to play
a role in the prognosis; the larger tumours in fact don't
seem more likely to recur than the smaller ones. In the
experience recently reported by Clayman neither local
Histological findings: H/E Figure 3
Histological findings: H/E a) papillary growth pattern, focal nuclear pleomorphism and multinucleate giant cells; b) diffuse, sheet 
like, growth pattern c) massive infiltration in an encapsulated nodule, suggesting metastatic lymphnode; d) vascular invasion in 
the soft tissue surrounding the parathyroid;World Journal of Surgical Oncology 2005, 3:39 http://www.wjso.com/content/3/1/39
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invasiveness seems to correlate with likelihood of recur-
rence [16,28]. Our case too confirms that many biologic
factors involved in the clinical course of parathyroid can-
cer remain unclear. Most of the parathyroid cancers are
diagnosed after surgery and often only after reoperation
for local or distant recurrence; many patients have a good
clinical course despite the type of the initial operation;
others have recurrent or persistent hypercalcemia and
severe metabolic complications that can be difficult to
control and often result in death [15]. The outcome of the
patients with parathyroid carcinoma depends on the bio-
logic features and on the management of the recurrent dis-
ease more than on initial therapy. In the future an
understanding of molecular pathogenesis of this rare
malignancy could provide a means for early diagnosis and
new treatment strategies. [16,29].
Conclusion
Based on current knowledge, clinicians should consider
parathyroid carcinoma in differential diagnosis when
patients present with severe hyperparathyroidism and a
palpable cervical mass. When there is an intraoperative
suspicion of malignancy, a complete surgical resection
should be undertaken with special attention to avoid the
rupture of the capsule of the tumour. We believe this
approach offers the best chance for a successful outcome.
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